Physician profile
Sujith Modugula
NPI 1780247627
$1,265.41
in general payments reported to CMS, 2019-2025
10 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $244 · 2023: $395 · 2024: $454 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.43 |
| Education | $170.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $347.14 | 2022-2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Astrazeneca Pharmaceuticals Lp | $266.86 | 2024-2025 | Fasenra, Saphnelo |
| Johnson & Johnson Health Care Systems INC. | $150.00 | 2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.35 | 2023 | Ofev |
| Glaxosmithkline, LLC. | $102.08 | 2022 | |
| Harmony Biosciences LLC | $99.99 | 2025 | |
| Sanofi-Aventis U.S. LLC | $70.99 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $70.87 | 2023-2024 | Dupixent |
| Mindray Ds USA, INC. | $29.60 | 2023 | Te7 Max, Te X |
| Amgen INC. | $23.53 | 2023 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujith Modugula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.